Source:http://linkedlifedata.com/resource/pubmed/id/20449885
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-5-6
|
pubmed:abstractText |
Unknown melanoma occurs as metastasis to skin, nodes or viscera, without a detectable cutaneous primary tumour. We reviewed our database of 4881 melanoma patients, diagnosed and followed up prospectively for a 33-year period. We identified 93 cases of metastatic melanoma without evidence of primary; however, five of these patients had a history of a previous excision of a presumed benign lesion without histological examination and were excluded from analyses. At diagnosis, metastases were cutaneous in 35.3% of cases, nodal in 43.2% and visceral in 17% of cases; in 4.5% of patients, both skin and nodes were involved. In all cases, clinical inspection and staging procedures performed at diagnosis of metastatic disease failed to identify a primary melanoma. In 11 cases (11.8%), extensively regressed pigmented lesions (without evidence of melanoma cells at the histological examination) were documented; moreover, we identified in our series five patients with unknown primary affected by vitiligo. The 5-year and 10-year overall survival rates were 49.6 and 41.4%, respectively, with a median of 4.9 years. The 5-year and 10-year time to progression rates were 39.4 and 32.3%, respectively, with a median of 2.3 years. Survival was longer in females and showed significant differences among patients with skin, lymph node or visceral involvement at diagnosis. In melanoma patients, unknown primary represents a not so rare event, with an uncertain origin. We confirmed the relatively good prognosis of unknown primary melanoma patients, a fact that has to be taken into consideration for their management.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
1473-5636
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
227-32
|
pubmed:meshHeading |
pubmed-meshheading:20449885-Adolescent,
pubmed-meshheading:20449885-Adult,
pubmed-meshheading:20449885-Aged,
pubmed-meshheading:20449885-Aged, 80 and over,
pubmed-meshheading:20449885-Disease Progression,
pubmed-meshheading:20449885-Female,
pubmed-meshheading:20449885-Humans,
pubmed-meshheading:20449885-Italy,
pubmed-meshheading:20449885-Male,
pubmed-meshheading:20449885-Melanoma,
pubmed-meshheading:20449885-Middle Aged,
pubmed-meshheading:20449885-Monophenol Monooxygenase,
pubmed-meshheading:20449885-Prospective Studies,
pubmed-meshheading:20449885-Skin Neoplasms,
pubmed-meshheading:20449885-Treatment Outcome
|
pubmed:year |
2010
|
pubmed:articleTitle |
Melanoma of unknown primary site: a 33-year experience at the Turin Melanoma Centre.
|
pubmed:affiliation |
Department of Biomedical Sciences and Human Oncology, Section of Clinics and Oncological Dermatology, University of Turin, Italy. paola.savoia@unito.it
|
pubmed:publicationType |
Journal Article
|